PRAXIS PRECISION MEDICINES, INC. (PRAX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Win.
24/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LosePRAX / S&P 3.91% / 15.20% |
LosePRAX / S&P PRAX unavailable / 15.00% |
LosePRAX / S&P 4.78% / 50.40% |
| 2026-Q11/3 |
WinPRAX / S&P 9.31% / -4.33% |
LosePRAX / S&P PRAX unavailable / 11.30% |
LosePRAX / S&P 24.12% / 27.70% |
| 2025-Q42/3 |
WinPRAX / S&P 456.11% / 2.65% |
LosePRAX / S&P -100.00% / 9.00% |
WinPRAX / S&P 30.40% / 13.40% |
| 2025-Q33/3 |
WinPRAX / S&P 26.04% / 8.12% |
WinPRAX / S&P 364.98% / 4.61% |
WinPRAX / S&P 39.50% / 13.45% |
| 2025-Q23/3 |
WinPRAX / S&P 11.04% / 10.94% |
WinPRAX / S&P 338.45% / 4.83% |
WinPRAX / S&P 33.37% / 10.63% |
| 2025-Q11/3 |
LosePRAX / S&P -50.79% / -4.27% |
WinPRAX / S&P 270.02% / 4.98% |
LosePRAX / S&P -27.65% / 10.57% |
| 2024-Q42/3 |
WinPRAX / S&P 33.75% / 2.41% |
WinPRAX / S&P 249.53% / 5.25% |
LosePRAX / S&P -54.37% / 6.15% |
| 2024-Q31/3 |
WinPRAX / S&P 39.12% / 5.89% |
LosePRAX / S&P -16.93% / 5.89% |
LosePRAX / S&P -89.27% / 6.11% |
| 2024-Q21/3 |
LosePRAX / S&P -32.22% / 4.28% |
WinPRAX / S&P 20.97% / 5.38% |
LosePRAX / S&P -89.08% / 5.12% |
| 2024-Q12/3 |
WinPRAX / S&P 173.88% / 10.56% |
WinPRAX / S&P 221.38% / 5.71% |
LosePRAX / S&P -81.07% / 5.59% |
| 2023-Q40/3 |
LosePRAX / S&P -13.14% / 11.69% |
LosePRAX / S&P PRAX unavailable / 6.81% |
LosePRAX / S&P -67.49% / 7.78% |
| 2023-Q32/3 |
WinPRAX / S&P 48.70% / -3.27% |
LosePRAX / S&P PRAX unavailable / 7.52% |
WinPRAX / S&P 1590.23% / -5.03% |
| 2023-Q22/3 |
WinPRAX / S&P 42.15% / 8.74% |
LosePRAX / S&P PRAX unavailable / 9.50% |
WinPRAX / S&P 1543.02% / -8.57% |
| 2023-Q11/3 |
LosePRAX / S&P -66.01% / 7.50% |
LosePRAX / S&P PRAX unavailable / 10.77% |
WinPRAX / S&P 1567.80% / -15.69% |
| 2022-Q41/3 |
LosePRAX / S&P 4.85% / 7.56% |
LosePRAX / S&P PRAX unavailable / 11.88% |
WinPRAX / S&P 1676.79% / -17.99% |
| 2022-Q30/3 |
LosePRAX / S&P -7.35% / -4.88% |
LosePRAX / S&P PRAX unavailable / 13.47% |
LosePRAX / S&P -131.84% / -1.41% |
| 2022-Q20/3 |
LosePRAX / S&P -76.00% / -16.10% |
LosePRAX / S&P PRAX unavailable / 13.71% |
LosePRAX / S&P -203.61% / 11.04% |
| 2022-Q11/3 |
LosePRAX / S&P -48.17% / -4.60% |
LosePRAX / S&P PRAX unavailable / 15.97% |
WinPRAX / S&P 95.04% / 42.23% |
| 2021-Q40/3 |
LosePRAX / S&P 6.54% / 11.03% |
LosePRAX / S&P PRAX unavailable / 15.00% |
LosePRAX / S&P PRAX unavailable / 96.40% |
| 2021-Q31/3 |
WinPRAX / S&P 1.15% / 0.58% |
LosePRAX / S&P PRAX unavailable / 10.77% |
LosePRAX / S&P PRAX unavailable / 69.42% |
| 2021-Q20/3 |
LosePRAX / S&P -44.20% / 8.55% |
LosePRAX / S&P PRAX unavailable / 6.58% |
LosePRAX / S&P PRAX unavailable / 51.81% |
| 2021-Q10/3 |
LosePRAX / S&P -40.46% / 6.17% |
LosePRAX / S&P PRAX unavailable / -1.06% |
LosePRAX / S&P PRAX unavailable / 7.39% |
| 2020-Q40/3 |
LosePRAX / S&P PRAX unavailable / 12.15% |
LosePRAX / S&P PRAX unavailable / -3.72% |
LosePRAX / S&P PRAX unavailable / -33.42% |
| 2020-Q30/3 |
LosePRAX / S&P PRAX unavailable / 8.93% |
LosePRAX / S&P PRAX unavailable / -2.04% |
LosePRAX / S&P PRAX unavailable / -27.10% |
| 2020-Q20/3 |
LosePRAX / S&P PRAX unavailable / 20.54% |
LosePRAX / S&P PRAX unavailable / -0.46% |
LosePRAX / S&P PRAX unavailable / -27.11% |
| 2020-Q10/3 |
LosePRAX / S&P PRAX unavailable / -19.60% |
LosePRAX / S&P PRAX unavailable / 3.47% |
LosePRAX / S&P PRAX unavailable / -14.75% |
| 2019-Q40/3 |
LosePRAX / S&P PRAX unavailable / 9.07% |
LosePRAX / S&P PRAX unavailable / 5.36% |
LosePRAX / S&P PRAX unavailable / 2.99% |
| 2019-Q30/3 |
LosePRAX / S&P PRAX unavailable / 1.70% |
LosePRAX / S&P PRAX unavailable / 5.02% |
LosePRAX / S&P PRAX unavailable / 0.21% |
| 2019-Q20/3 |
LosePRAX / S&P PRAX unavailable / 4.30% |
LosePRAX / S&P PRAX unavailable / 6.64% |
LosePRAX / S&P PRAX unavailable / 8.65% |
| 2019-Q10/3 |
LosePRAX / S&P PRAX unavailable / 13.65% |
LosePRAX / S&P PRAX unavailable / 8.12% |
LosePRAX / S&P PRAX unavailable / 14.29% |
| 2018-Q40/3 |
LosePRAX / S&P PRAX unavailable / -13.52% |
LosePRAX / S&P PRAX unavailable / 9.05% |
LosePRAX / S&P PRAX unavailable / 18.23% |
| 2018-Q30/3 |
LosePRAX / S&P PRAX unavailable / 7.71% |
LosePRAX / S&P PRAX unavailable / 10.21% |
LosePRAX / S&P PRAX unavailable / 19.06% |
| 2018-Q20/3 |
LosePRAX / S&P PRAX unavailable / 3.43% |
LosePRAX / S&P PRAX unavailable / 9.03% |
LosePRAX / S&P PRAX unavailable / 14.46% |
| 2018-Q10/3 |
LosePRAX / S&P PRAX unavailable / -0.76% |
LosePRAX / S&P PRAX unavailable / 7.68% |
LosePRAX / S&P PRAX unavailable / 12.46% |
| 2017-Q40/3 |
LosePRAX / S&P PRAX unavailable / 6.64% |
LosePRAX / S&P PRAX unavailable / 7.03% |
LosePRAX / S&P PRAX unavailable / 13.82% |
| 2017-Q30/3 |
LosePRAX / S&P PRAX unavailable / 4.48% |
LosePRAX / S&P PRAX unavailable / 5.68% |
LosePRAX / S&P PRAX unavailable / 17.57% |
| 2017-Q20/3 |
LosePRAX / S&P PRAX unavailable / 3.09% |
LosePRAX / S&P PRAX unavailable / 4.83% |
LosePRAX / S&P PRAX unavailable / 17.74% |
| 2017-Q10/3 |
LosePRAX / S&P PRAX unavailable / 6.07% |
LosePRAX / S&P PRAX unavailable / 3.67% |
LosePRAX / S&P PRAX unavailable / 13.32% |
| 2016-Q40/3 |
LosePRAX / S&P PRAX unavailable / 3.82% |
LosePRAX / S&P PRAX unavailable / 2.09% |
LosePRAX / S&P PRAX unavailable / 7.05% |
| 2016-Q30/3 |
LosePRAX / S&P PRAX unavailable / 3.85% |
LosePRAX / S&P PRAX unavailable / 0.20% |
LosePRAX / S&P PRAX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | PRAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 707.75% | 20.78% |
| Annualized return | 707.75% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | PRAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 24.48% | 83.14% |
| Annualized return | 4.48% | 12.86% |
10Y · 2020-10-16 to 2026-08-27
| Metric | PRAX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -11.79% | 319.30% |
| Annualized return | -1.25% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |